Bil Jacek, Gil Robert J, Vassilev Dobrin
Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior Warsaw, Poland.
Institute of Experimental and Clinical Medicine, Polish Academy of Science Warsaw, Poland.
Interv Cardiol. 2015 May;10(Suppl 1):3-6. doi: 10.15420/icr.2015.10.2.S1.
The BiOSS LIM® (Bifurcation Optimization Stent System, Balton, Warsaw, Poland) stent is a coronary, dedicated bifurcation, balloonexpandable stent made of 316 L stainless steel with a strut thickness of 120 μm. It is covered with a mixture of a biodegradable polymer and the antiproliferative substance: sirolimus. The stent consists of two parts (the proximal with a larger diameter in relation to the distal one) connected with two struts (average 1.5 mm length) at the middle zone. The stent is crimped on a bottle-shaped semi-compliant balloon (Bottle®, Balton, Warsaw, Poland). Our intravascular ultrasound (IVUS) study revealed that the construction of the BiOSS® stent allows easy access to the side branch, similar to the classic stent lumen enlargement with less injury to the area adjacent to the most sensitive part of the bifurcation. The BiOSS LIM® stent has already been thoroughly investigated: initially in the First-In-Man registry with 60 patients, then in the registry in a high-risk population with distal left main stenosis and finally in a randomised clinical trial POLBOS II. The long-term clinical results were satisfactory and closely related to the high-risk profile of the treated population. Our data demonstrated that the simple and fast bifurcation treatment with a single dedicated bifurcation sirolimus-eluting stent (BiOSS LIM®) is feasible and highly successful.
BiOSS LIM®(分叉优化支架系统,Balton,华沙,波兰)支架是一种冠状动脉专用分叉球囊扩张支架,由316L不锈钢制成,支柱厚度为120μm。它覆盖有可生物降解聚合物和抗增殖物质西罗莫司的混合物。该支架由两部分组成(近端直径相对于远端更大),在中间区域通过两个支柱(平均长度1.5mm)连接。该支架被压握在瓶形半顺应性球囊(Bottle®,Balton,华沙,波兰)上。我们的血管内超声(IVUS)研究表明,BiOSS®支架的结构便于进入侧支,类似于经典的支架管腔扩大,对分叉最敏感部位附近区域的损伤较小。BiOSS LIM®支架已经经过了充分研究:最初在60例患者的首次人体注册研究中,然后在远端左主干狭窄的高危人群注册研究中,最后在随机临床试验POLBOS II中。长期临床结果令人满意,并且与所治疗人群的高危特征密切相关。我们的数据表明,使用单一专用分叉西罗莫司洗脱支架(BiOSS LIM®)进行简单快速的分叉治疗是可行且非常成功的。